We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 117

Do DNA patents affect genetic sequencing and testing advances?
  • Shook Hardy & Bacon LLP
  • USA
  • November 15 2012

University of Missouri-Kansas City School of Law Professor Christopher Holman writes in the most recent issue of Nature Technology that while DNA sequencing technology has spawned a myriad of patent-related lawsuits, “aggressive patent acquisition and enforcement practices” show no signs of abating and may not necessarily be hindering the development of next-generation DNA sequencing and analysis technologies


News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • October 3 2012

U.S. Health and Human Services Secretary Kathleen Sebelius delegates authority to the Food and Drug Administration (FDA) to determine whether clinical trial information was not submitted to the Clinical Trial Registry and Results Data Bank as required by law or “was submitted but is false or misleading in any particular.”


Drug patent-protection incentives needed?
  • Shook Hardy & Bacon LLP
  • USA
  • June 12 2014

Noting that several members of Congress recently demanded that a pharmaceutical company justify the high cost of its hepatitis C drug, the


Federal court upholds FTC rules on reporting certain pharma patent transfers
  • Shook Hardy & Bacon LLP
  • USA
  • June 12 2014

Granting the agency's motion for summary judgment, a federal court in the District of Columbia has upheld the U.S. Federal Trade Commission's (FTC's


Court finds no standing for Consumer Watchdog in stem cell patent appeal
  • Shook Hardy & Bacon LLP
  • USA
  • June 12 2014

The Federal Circuit Court of Appeals has rejected not-for-profit Consumer Watchdog's appeal of the U.S. Patent and Trademark Office's (USPTO's


News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • October 30 2014

The U.S. Food and Drug Administration (FDA) makes available Guidance for Industry titled "Circumstances that Constitute Delaying, Denying, Limiting


News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • August 7 2014

The U.S. Patent & Trademark Office (USPTO) selects 19 law schools to join its Law School Clinic Certification Pilot Program. Four of the law schools


Analysts predicts biosimilars boom as biologics reach new patent cliff
  • Shook Hardy & Bacon LLP
  • Global
  • August 7 2014

A new Allied Market Research (AMR) report predicts that the global biosimilars market, which accounted for $1.3 billion in 2013, will generate $35


EU Court of Justice Advocate General issues ruling on Stem Cell patentability
  • Shook Hardy & Bacon LLP
  • European Union, United Kingdom
  • August 7 2014

In a non-binding ruling, Advocate General Cruz Villalón of the EU Court of Justice has determined that unfertilized human ova whose division


News bytes
  • Shook Hardy & Bacon LLP
  • USA
  • November 13 2014

The U.S. Food and Drug Administration (FDA) makes available Guidance for Industry and staff titled "Molecular Diagnostic Instruments with Combined